Company Overview and News
Mumbai: Tata Consultancy Services Ltd’s (TCS) market cap surged past the ₹ 8 trillion mark for the first time today, making it only the second Indian company to achieve the milestone after Reliance Industries Ltd (RIL). TCS share prices rose 1.7% to a record high of ₹ 2091 on the BSE today, imparting the IT bellwether a market cap of ₹ 8.01 trillion.
500325 RELIANCE TATAPOWER TTNQY 500470 532540 TTST TATAINVEST TATASTEEL TATLY RIGD 501301 TPCL 500400 TCS RLNIY
It appears there is finally some resolution in the eighteen-month-long battle between the Tata Sons and Cyrus Mistry at the National Company Law Tribunal (NCLT). Today, the NCLT dismissed Cyrus Mistry’s plea for his alleged illegal removal from the post of Tata Sons’ Chairman. And that is our Pick of the Day.
500408 TTML TATACOFFEE 500800 BHUSANSTL TTAZF TTQQY BHRQY TATACOMM TTNQY TATACHEM TTAEY 532301 TGBL 500470 532540 TATAINVEST TATASPONGE 501301 500570 BHARTIARTL TATAMOTORS 500770 500055 513010 TGBA TATAMETALI TATAPOWER 513434 532454 TTST TATASTEEL TATLY 532371 TPCL TATAELXSI TCS 500400 500483 TATAGLOBAL TTM
Tata Group stocks gained on Monday after the National Company Law Tribunal ruled in favour of Tata Sons against Cyrus Mistry's plea with regards to his removal as Tata Sons Chairman.
500408 TTML TTQQY TATACOMM TTNQY TATACHEM 500470 532540 TATAINVEST TATASPONGE 501301 500570 TATAMOTORS 500770 513010 TATAMETALI TATAPOWER 513434 TTST TATASTEEL TATLY 532371 TPCL TATAELXSI TCS 500400 500483 TTM
Saturday-Monday will see close to two dozen companies announcing their quarterly and full-year results for FY 2018. These are Avenue Supermarts, Balaxi Ventures, DIC India, JP Power and Jayant Agro (on Saturday); Intellect Design Arena (Sunday); and Filatex, Firstsource, Hinduja Ventures, ICICI Bank, INOX Leisure, Pfizer, Rane Holdings, Software Group, Shalby, Tata Chemicals, Tata Coffee, Tata Investment, Trident, Tube Investments, Vijaya Bank and Zee Learn (on Monday).
DICIND ZEELEARN TATACOFFEE IBN 532706 TTQQY INOXLEISUR 533287 538835 TATACHEM 532401 VIJAYABANK 532301 HINDUJAVEN ICICIBANK RANEHOLDIN TATAINVEST 532174 501301 500189 INTELLECT 505800 500770 500089
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...